Delphia Therapeutics operates and manages a laboratory that develops treatments for cancer cells.
Delphia Therapeutics has raised $67.0M in total funding. The most recent round was Series A. The last funding was announced in May 2024.
Delphia Therapeutics's investors include Polaris Partners, Google Ventures, Alexandria Venture Investments, Nextech Invest.
Delphia Therapeutics is headquartered in Cambridge, United States.
Delphia Therapeutics operates and manages a laboratory that develops treatments for cancer cells.
Delphia Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Delphia Therapeutics — Funding & Investors." VCBacked, May 2, 2024, https://www.vcbacked.co/company/delphia-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). Delphia Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/delphia-therapeutics
{{cite web |title=Delphia Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/delphia-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated